The Cambridge Public Health Commission

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Depakote-ER for Depressive and Bipolar Depression

Phase 4
Completed
Conditions
Bipolar Disorder
First Posted Date
2005-09-27
Last Posted Date
2017-04-18
Lead Sponsor
Cambridge Health Alliance
Target Recruit Count
25
Registration Number
NCT00226343

Aripiprazole in the Treatment of Bipolar Depression

Not Applicable
Completed
Conditions
Bipolar Disorder
Interventions
Drug: Aripiprazole
First Posted Date
2005-09-27
Last Posted Date
2017-04-18
Lead Sponsor
Cambridge Health Alliance
Target Recruit Count
20
Registration Number
NCT00226317
Locations
🇺🇸

Cambridge Health Alliance, Cambridge, Massachusetts, United States

Natural Supplements for Unipolar Depression

First Posted Date
2005-09-27
Last Posted Date
2017-04-18
Lead Sponsor
Cambridge Health Alliance
Target Recruit Count
20
Registration Number
NCT00226356
Locations
🇺🇸

Cambridge Health Alliance, Cambridge, Massachusetts, United States

A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder

Phase 4
Completed
Conditions
Bipolar Disorder
Interventions
Drug: Placebos
Drug: Galantamine
First Posted Date
2005-09-20
Last Posted Date
2017-04-18
Lead Sponsor
Cambridge Health Alliance
Target Recruit Count
30
Registration Number
NCT00195845
Locations
🇺🇸

Cambridge Health Alliance, Cambridge, Massachusetts, United States

The Trauma Recovery and Resiliency Research Project

First Posted Date
2005-08-18
Last Posted Date
2017-04-18
Lead Sponsor
Cambridge Health Alliance
Target Recruit Count
969
Registration Number
NCT00131534
Locations
🇺🇸

Victims of Violence Program, Cambridge Health Alliance, Somerville, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy